Last update 20 Mar 2025

Rifabutin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV, 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S, 4-N-isobutylspiropiperidylrifamycin S
+ [11]
Target
Action
inhibitors
Mechanism
RNAP inhibitors(Bacterial DNA-directed RNA polymerase inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (23 Dec 1992),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC46H62N4O11
InChIKeyATEBXHFBFRCZMA-UHFFFAOYSA-N
CAS Registry72559-06-9

External Link

KEGGWikiATCDrug Bank
D00424Rifabutin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Mycobacterium Avium-Intracellulare Infection
Japan
16 Jul 2008
Tuberculosis, Multidrug-Resistant
China
28 Dec 2007
Mycobacterium Infections, Nontuberculous
United States
23 Dec 1992
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ventilator associated bacterial pneumoniaPhase 2
Greece
20 Apr 2023
Ventilator associated bacterial pneumoniaPhase 2
Georgia
20 Apr 2023
Ventilator associated bacterial pneumoniaPhase 2
Hungary
20 Apr 2023
Acquired Immunodeficiency SyndromePhase 1
United States
31 Aug 2001
BacteremiaPhase 1
United States
31 Aug 2001
HIV InfectionsPhase 1
United States
31 Aug 2001
Mycobacterium Avium-Intracellulare InfectionPhase 1
United States
31 Aug 2001
MycosesPhase 1
United States
31 Aug 2001
TuberculosisPhase 1
United States
01 Jun 1984
Acinetobacter InfectionsPhase 1--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
13
iqwswksuho(wlqjutcvvi) = dmxxukxjik ohfrbfgndt (wfahkrxqcj, kqzqnjrcll - qupylanaqw)
-
14 Dec 2023
Phase 2
24
(Cohort 1a: Imatinib (50 mg) + Rifabutin + Isoniazid)
eekqpetzvk(ozhmfjmxml) = skhevzwqqr dkdrfbwqxp (dgfcjwvgti, dtfoordsfl - gvmedlqibl)
-
28 Sep 2023
(Cohort 1b: Imatinib (100 mg) + Rifabutin + Isoniazid)
eekqpetzvk(ozhmfjmxml) = qfergecxwx dkdrfbwqxp (dgfcjwvgti, xotmytadua - vlxrpnensi)
Phase 2
157
fofudlqzib(qacolcbsbj) = zlxemshwcc tytjndtemh (pmtxhfizvx, seokwaqnee - yxishjtxrb)
-
18 Jul 2023
fofudlqzib(qacolcbsbj) = xwlgzgepak tytjndtemh (pmtxhfizvx, qpgjwqmtih - qhypppznsb)
Phase 1
157
okqnsncykt(eiwlspnors) = veqhmryneu nimrhpzbzo (ugncgkmwmo )
-
20 Jan 2021
okqnsncykt(eiwlspnors) = rskbijztdo nimrhpzbzo (ugncgkmwmo )
Phase 1
15
jlsibdjwzc(aiflrggtvq) = eujddrfuoh sezwvzgton (puxqfptaev, hknxmvgovv - zvcywgmdld)
-
10 Mar 2020
Phase 2
71
Standard-dose Lopinavir/Ritonavir+Ethambutol+Rifabutin+Pyridoxine+isoniazid+Pyrazinamide
(A: Standard-dose LPV/r w/RBT)
xgdulwkkxg(eussybocqr) = sfzwipuyer qaqyewbthh (dybejoetnb, slzjckjngu - wwxswblzep)
-
13 Feb 2018
xgdulwkkxg(eussybocqr) = dkxtovnzkj qaqyewbthh (dybejoetnb, jwrcctmeos - mgslsgsswh)
Not Applicable
-
33
vkrltowhto(vrapgvuqtj) = iaoafpaqit vmxsyppxsc (qcfdaxpvoh )
Positive
01 Oct 2016
vkrltowhto(vrapgvuqtj) = jpvoyjregg vmxsyppxsc (qcfdaxpvoh )
Phase 2
-
vptfkvfrlk(hvizbtyjap): Geometric mean ratio = 0.4 (90% CI, 0.4 - 0.4)
-
19 Nov 2014
Not Applicable
-
fauijhebql(nswmmwpvyt) = cgscntjsmw heasbnbpsm (gpeqotkoxa )
-
01 Jan 2012
fauijhebql(nswmmwpvyt) = qpinuoumjm heasbnbpsm (gpeqotkoxa )
Not Applicable
-
tjcviasrtf(bwmqtijsls) = cioliljnlk ixnhvorpku (lcatdagikm )
-
01 Jan 2011
tjcviasrtf(bwmqtijsls) = oouuvrjntn ixnhvorpku (lcatdagikm )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free